Fetal Bovine Serum for Pharmaceutical Applications
Pharmaceutical manufacturing and GMP-grade bioprocessing place significantly higher demands on fetal bovine serum than standard research applications. Regulatory submissions to the EMA and FDA require documented serum origin, adventitious agent testing to Ph. Eur. and USP standards, TSE risk assessment, and — increasingly — lot reservation to ensure manufacturing consistency from process development through clinical batch production.
SeamlessBio supplies pharmaceutical-grade FBS with full documentation packages, multiple geographic origins, and gamma irradiation on request, supported by batch reservation for GMP and pre-GMP manufacturing campaigns.
Available Origins
| Origin | TSE Risk Classification | Primary Use Case |
|---|---|---|
| United States | USDA-regulated; negligible BSE risk per EMA/CHMP/BWP | FDA IND/BLA submissions; US-origin preference for USFDA-regulated products |
| Australia | Negligible BSE risk; APVMA-regulated | EMA submissions; lowest TSE risk documentation burden; preferred for EU MAA |
| New Zealand | Negligible BSE risk; MPI-regulated | EMA submissions; equivalent TSE risk profile to Australia; EU MAA preferred |
| EU Origin | Controlled BSE risk; EU-regulated herd surveillance | EMA submissions requiring EU-origin preference; simplified import documentation |
Pharmaceutical-Grade Specifications
| Parameter | Standard | Available Grade |
|---|---|---|
| Sterility | Ph. Eur. 2.6.1 / USP <71> | All pharma-grade lots |
| Mycoplasma | Ph. Eur. 2.6.7 / USP <63> | All pharma-grade lots |
| Endotoxin (LAL) | Ph. Eur. 2.6.14 / USP <85> | <1 EU/mL (Low Endotoxin grade) |
| Viral safety (BVDV, BVV) | Ph. Eur. 5.2.3 / ICH Q5A | Lot-specific viral testing; PCR and infectivity methods |
| Haemoglobin | Spectrophotometric | <20 mg/dL standard; lower on request |
| Protein concentration | Bradford / BCA | Lot-specific; typically 35–45 mg/mL |
| Gamma irradiation | ≥25 kGy minimum absorbed dose | On request; dose mapping certificate included |
| Heat inactivation | 56°C / 30 min | On request; complement activity confirmed <10% |
Documentation Package
Every pharmaceutical-grade FBS lot from SeamlessBio includes a complete documentation package aligned with EMA CHMP/BWP and FDA regulatory expectations:
- Certificate of Analysis (CoA) — protein concentration, endotoxin, sterility, mycoplasma, haemoglobin, pH
- Certificate of Origin — country of origin, slaughterhouse approval documentation
- TSE/BSE Risk Assessment — country-specific risk classification per EMA CHMP/BWP/457920/2012
- Viral Safety Testing Report — BVDV (cytopathic and non-cytopathic strains), BVV, REO-3 per Ph. Eur. 5.2.3
- Gamma Irradiation Certificate — irradiator validation, dose mapping, absorbed dose confirmation (on request)
- Animal-Derived Components Declaration — for regulatory submissions requiring ADCD documentation
Batch Reservation for GMP Manufacturing
Pharmaceutical manufacturing processes validated with a specific FBS lot cannot tolerate unplanned lot changes. SeamlessBio offers batch reservation for pharma customers — securing a dedicated volume of a single lot from process development through final GMP manufacturing batch. Typical reservation periods: 12–36 months depending on manufacturing campaign duration.
Batch reservation is available for:
- Cell therapy and ATMP process development to clinical manufacturing
- Viral vaccine substrate cell line maintenance
- Biopharmaceutical production cell line (HEK293, CHO, Vero, MDCK) expansion
- AAV vector manufacturing (Tet-Free grade required for inducible systems)
Available Specialty Grades for Pharma
| Grade | Key Specification | Pharma Application |
|---|---|---|
| FBS Low Endotoxin | <1 EU/mL | GMP cell culture; minimises pyrogenic risk in manufacturing media |
| FBS Gamma Irradiated | ≥25 kGy, dose-mapped | BSL-2/3 viral vaccine production; enhanced viral safety margin |
| FBS Tet-Free | Tetracycline <10 ng/mL | Inducible expression systems (AAV, lentiviral packaging, CAR-T) |
| FBS Ultra Low IgG | IgG <5 µg/mL | Downstream purification; reduces bovine IgG co-elution on Protein A columns |
| FBS Heat Inactivated | 56°C / 30 min | Complement-sensitive manufacturing processes; T cell expansion |
→ View and order FBS grades at shop.seamlessbio.de
→ Batch reservation, documentation packages, and GMP supply enquiries: info@seamlessbio.de | +49 851 37932226